Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123, a MethionyltRNA Synthetase Inhibitor Developed for Treatment of Clostridium difficile, in a Phase 1 Study Article (Web of Science)

International Collaboration

cited authors

  • Nayak, Seema U.; Griffiss, J. McLeod; Blumer, Jeffrey; O'Riordan, Mary Ann; Gray, Wesley; McKenzie, Robin; Jurao, Robert A.; An, Amanda T.; Le, Melissa; Bell, Stacie J.; Ochsner, Urs A.; Jarvis, Thale C.; Janjic, Nebojsa; Zenilman, Jonathan M.

publication date

  • August 1, 2017

webpage

published in

category

keywords

  • CRS3123
  • Clostridium difficile
  • Gram-positive bacteria
  • antimicrobial agents
  • glucuronidation
  • pharmacokinetics

volume

  • 61

issue

  • 8